Multiple sclerosis is characterised by inflammatory neurodegeneration, with axonal injury and neuronal cell death occurring in parallel to demyelination. Regarding the molecular mechanisms responsible for demyelination and axonopathy, energy failure, aberrant expression of ion channels and excitotoxicity have been suggested to lead to Ca 2+ overload and subsequent activation of calcium-
dependent damage pathways. Thus, the inhibition of Ca 2+ influx by pharmacological modulation of Ca 2+ channels may represent a novel neuroprotective strategy in the treatment of secondary axonopathy. We therefore investigated the effects of the L-type voltage-gated calcium channel blocker nimodipine in two different models of mouse experimental autoimmune encephalomyelitis (EAE), an established experimental paradigm for multiple sclerosis. We show that preventive application of nimodipine (10 mg/kg per day) starting on the day of induction had ameliorating effects on EAE in SJL/J mice immunised with encephalitic myelin peptide PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] , specifically in late-stage disease. Furthermore, supporting these data, administration of nimodipine to MOG -immunised C57BL/6 mice starting at the peak of pre-established disease, also led to a significant decrease in disease score, indicating a protective effect on secondary CNS damage. Histological analysis confirmed that nimodipine attenuated demyelination, axonal loss and pathological axonal b-amyloid precursor protein accumulation in the cerebellum and spinal cord in the chronic phase of disease. Of note, we observed no effects of nimodipine on the peripheral immune response in EAE mice with regard to distribution, antigen-specific proliferation or activation patterns of lymphocytes. Taken together, our data suggest a CNS-specific effect of L-type voltage-gated calcium channel blockade to inflammation-induced neurodegeneration. Keywords: experimental autoimmune encephalomyelitis, Ltype VGCC, nimodipine. J. Neurochem. (2018) 146, 86--98.
Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system (CNS) affecting around 2.5 million people worldwide. According to our current understanding, activated myelin-reactive T lymphocytes escape immunoregulatory mechanisms, enter the brain and spinal cord and initiate a local immune attack against the myelin sheath (Compston and Coles 2008) . The resulting tissue damage characterised by demyelination and relative axonal preservation has been considered typical of MS (Stadelmann 2011) . However, in the last decade, evidence accumulated from brain pathology and magnetic resonance imaging studies in MS patients showed that axonal and neuronal damage is an early feature of MS that contributes to long-term disability (Trapp et al. 1998; De Stefano et al. 2001; Pirko et al. 2011) . Experimental work mainly based on a common animal model, experimental autoimmune encephalomyelitis (EAE) usually induced by immunisation with myelin antigens, indicates that collateral damage to neuronal structures may occur during acute inflammation caused by anti-myelin immune responses (Aktas et al. 2005; Sobottka et al. 2009; Siffrin et al. 2010) . Moreover, neuropathology in MS and in certain variants of EAE shows chronic neurodegeneration exceeding the demyelinated area (Evangelou et al. 2000; Kutzelnigg et al. 2005; Vogt et al. 2009; Schirmer et al. 2011) . Regarding the underlying mechanisms, recent reports suggested the contribution of failed energy metabolism (Kapoor et al. 2003; Dutta et al. 2006) and altered ion channel homeostasis in MS (Waxman 2006; Aktas et al. 2010) . In neurons, the impairment of mitochondrial respiration and ATP generation leads to the gradual loss of function of the Na + /K + ATPase and subsequent changes of the transmembrane ionic gradient. The ionic imbalance because of the inefficient Na + export and permanent membrane depolarisation leads to an increased activity of the Na + /Ca 2+ exchanger that initiates Ca 2+ transport into axons to compensate the Na + influx (Waxman 2006; Aktas et al. 2010) . Moreover, glutamate-induced excitation has a direct impact on local axonal Ca 2+ release from intracellular stores resulting in axonal damage in pathological conditions, the mechanism that involves the activation of plasma membrane L-type Ca 2+ channels (Ouardouz et al. 2003) . As shown in progressive MS, accumulation of Ca 2+ in demyelinated axons is followed by signs of Ca 2+ -dependent protease activity such as fragmented neurofilaments and depolymerised microtubules (Dutta et al. 2006) . Supporting this view, Na + channel blockers and inhibitors of Na + /Ca 2+ exchanger have shown neuroprotective effects in experimental models of ischaemic injury (Waxman et al. 1993; Stys and LoPachin 1997; Li et al. 2000) .
In another approach, therapeutic application of bepridil and nitrendipine, two voltage-gated Ca 2+ channel (VGCC) blockers, had a beneficial effect in murine EAE. Application of these substances delayed the onset of disease and resulted in clinical as well as pathological amelioration with reduced demyelination and axon pathology as well as inflammatory infiltration in the spinal cord (Brand-Schieber and Werner 2004) . However, it remained open whether these substances exert direct neuroprotective or rather immunomodulatory effects as expression of regulatory b and Ca(v)1 subunits mediating Ltype Ca 2+ currents have been described for na€ ıve and activated CD4 + and CD8 + T cells (Badou et al. 2006; Jha et al. 2009; Cabral et al. 2010) , as well as for axons (Brown et al. 2001) and oligodendrocytes (Liu et al. 1997) .
Based on the contribution of L-type VGCCs to Ca 2+ release from intracellular stores (Chavis et al. 1996; Mouton et al. 2001; Ouardouz et al. 2003) and their involvement in Ca 2+ -dependent cell death (Stanika et al. 2012) , we aimed to assess the therapeutic effect of nimodipine, a dihydropiridine-based Ca 2+ channel blocker with pronounced lipophilic properties that selectively binds to L-type VGCCs. Nimodipine has been reported to confer neuroprotection in various in vivo models of cerebral ischaemia (Horn et al. 2001) , ischaemic spinal cord white matter damage (Ouardouz et al. 2003) and in an in vitro model of b-amyloid-induced neurotoxicity (Weiss et al. 1994) . Nimodipine is currently used in clinical practice for the prevention of cerebral vasospasms following subarachnoid haemorrhage, with a safe benefit/risk profile (Allen et al. 1983) . In the present work, we report the beneficial effect of preventive and therapeutic treatments with nimodipine on the disease course and the damage pattern in EAE, without detection of a relevant effect on the primary autoimmune response.
Materials and methods

Experimental autoimmune encephalomyelitis
All experimental procedures were conducted following to guidelines and protocols approved by the local animal welfare committee [Landesamt f€ ur Natur, Umwelt und Verbraucherschutz NordrheinWestfalen (LANUV)] under protocol numbers 84-02.2011.A163 and 84-02.04.2016 .A137; the ARRIVE criteria and EAE induction guideline (Kilkenny et al. 2010 ). This purely animal-based study was not pre-registered. A number of measures were taken to minimise animal suffering according to the local welfare committee requirements including (but not limited to) minimising the animal numbers using power calculation, intensified animal monitoring in case of worsening and implementation of specific criteria of animal sacrifice (neurological signs, loss of weight). Specific pain reducing medication was not applied and deemed necessary by the local welfare committee. Power calculations for EAE experiments were performed for sample size to reach statistical significance at a level of p < 0.05 using 95% power analysis. Five-to six-week-old female SJL/J (RRID:IMSR_JAX:000686) and C57BL/6 (RRID: IMSR_JAX:000664) mice were purchased from Janvier (Le Genest-St-Isle, France). Before (1-week acclimation period) and during the experiments, mice were housed under specific pathogen-free conditions in a reverse light/dark cycle, at a temperature of 22 AE 2°C, with water and food available ad libitum in compliance with institutional guidelines (Heinrich-Heine-University, D€ usseldorf, Germany). Animals suffering from EAE were granted easier access to water and food. Randomisation of animals was performed by a third person that was not involved in daily neurological scoring and treatment. Animals were allocated to cages with pseudonyms (A, B, etc.) with 4-5 animals per cage using a web-based computergenerated randomisation method (http://www.pubmed.de/tools/zufa llsgenerator). Scoring was performed by experimenters blinded to the pseudonyms. Yet, other experimenters performed animal scoring and the daily treatment, which was also blinded using pseudonyms (substance A, B). Blinding of the vehicle and nimodipine solutions was performed by a person that prepared those solutions and that was not involved in scoring or treatment. In established EAE with animals of differing neurological scores, randomisation can lead to unwanted random bias favouring one group even before treatment has started. In order to prevent this, the person in charge of randomisation first grouped the individual animals with score 2.5-3 into groups with equal neurological scores and then performed separate randomisations from these specific groups into the two treatment groups, thus providing proper randomisation, as well as equal scores of the two treatment groups before starting treatment. For relapsing-remitting EAE (Aktas et al. 2003) 
Histology and immunofluorescence microscopy
Immunohistochemistry Demyelination and axonal damage were assessed by immunohistochemistry and fluorescence microscopy. Tissue was dissected and fixed in 4% paraformaldehyde/PBS (24 h, 4°C), cryoprotected with 20% sucrose solution over night at 4°C, frozen in TissueTek O.C.T compound (cat# 4583; Sakura, Alphen aan den Rijn, Netherlands) and was further sectioned coronally on a cryostat (CM1900; Leica, Nussloch, Germany) into 20 lm thickness slices. The primary and secondary antibodies (for details see Table S1 ) were used according to the manufacturers' instructions. We analysed tissue from three representative mice per treatment group, according to clinical phenotype and mean clinical score of the respective group. At least three random sagittal brain sections and three axial spinal cord sections from lumbar vertebrae for each mouse were analysed. Images were taken by fluorescent microscope BX51 F-view CCD camera equipped with Olympus CellA imaging software (Olympus, Hamburg, RRID:SCR_014342) and analysed in Adobe Photoshop software (Adobe, Systems, San Jose, CA, RRID:SCR_014199).
Immunostaining of cerebellar sections for amyloid precursor protein (Bio-Rad Laboratories, Hercules, CA, USA/AbD Serotec, Puchheim, Germany Cat# AHP677, RRID:AB_2242734), a marker for compromised axonal transport, was used to quantify the number of axonal ovoids per 10 lm of axonal length identified with neurofilament H (NFL-H; Sigma-Aldrich Cat# N5389, RRID:AB_260781) antibody. 4-5 sections per mouse (in total four mice of each group) were examined.
Luxol fast blue staining
Spinal cord sections were first stained with eosin Y (Cat# 230251; Sigma-Aldrich, Schnelldorf, Germany) and a myelin stain was performed using Luxol fast blue stain (myelin kit, Cat# AB150675; Abcam, Cambridge, UK) based on the manufacturer's instructions. Four representative mice per treatment group were analysed, according to clinical phenotype and mean clinical score of the respective group. Four to five different sections per mouse were analysed under light microscopy (109 magnification). At least three randomly distributed fields within the white matter of anterior/ laterala and posterior funiculi were captured for each section. An average value of the Luxol fast blue burden was determined for each mouse. Tissue pathology (demyelination and axonal loss) was quantified by a blind assessment of two independent observers (L.D.S., T.P., J.G.) following a semi-quantitative score: 0 = normal tissue; 1 = 25% reduction of myelin basic protein (MBP) (Luxol fast blue burden or NF-M) signal; 2 = 50% reduction signal; 3 = 75% reduction of signal; 4 = complete loss of MBP (Luxol fast blue burden or NF-M) signal.
Flow cytometry
Cell surface antigens cells were detected with fluorochromeconjugated antibodies (for details see Table S1 ). Data acquisition and analysis were conducted on the FACSCanto II Flow Cytometer with FACSDiva Software (Becton-Dickinson, Franklin Lakes, NJ, USA, RRID:SCR_001456) and FACS Calibur Flow Cytometry System (Becton-Dickinson, RRID:SCR_000401) with Flowjo software (Becton-Dickinson, RRID:SCR_000410). Spleen cells from vehicle-and nimodipine-treated C57BL/6 EAE mice (n = 4 per each group, day 54) were re-stimulated for 48 h with myelin oligodendrocyte glycoprotein (MOG) (10 lg/mL) or anti-CD3
(1 lg/mL; Thermo Fisher Scientific Cat# 14-0031-81, RRID: AB_467048). Flow cytometry was performed to quantify mean fluorescence intensity in CD4 cells for activation markers.
Proliferation assay
Spleen cells were isolated at day 54 p.i. and were cultured in the presence of recombinant MOG or PLP 139-155 peptide (Pepceuticals) and anti-CD3 antibody (1 lg/mL; Thermo Fisher Scientific Cat# 14-0031-81, RRID:AB_467048). After 54 h, 0.5 lCi 3H-thymidine was added to each well. 18 h later (i.e. 72 h after restimulation) cells were harvested and the relative proliferation rate was measured as counts per minute (cpm) in a scintillation b counter (MicroBeta, Wallac, Finland).
Western blot analysis
The homogenates of the brain and spinal cord tissues were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (any KD mini-PROTEAN TGX Gels; Bio-Rad) and transferred to 0.2 lm nitrocellulose membrane (Bio-Rad) at 25 V, 2.5 A for 7 min, using the TransBlot Turbo Transfer System (Bio-Rad). The membrane was blocked with 5% bovine serum albumin in Tris-buffered saline and 0.05% Tween-20 for 2 h at 20°C and incubated with the primary antibodies (for details see Table S1 ) overnight at 4°C. Primary antibodies were detected by incubation with IR-Dye (680 or 800) secondary antibodies (Table S1 ) for 1 h at 20°C. Membranes were scanned using the Odyssey Imaging System (Li-COR, Lincoln, USA) and specific immunoreactive bands were quantified by computer-assisted densitometry (ImageJ software, National Institutes of Health, Bethesda, MD, USA RRID:SCR_003070). Probing with mouse anti-b-actin (1 : 5000; Sigma-Aldrich Cat# A3853, RRID: AB_262137) was used as a loading control and for normalisation.
RNA isolation, cDNA synthesis and qPCR RNA was isolated from spinal cords with Trizol (Invitrogen Life Technologies, Darmstadt, Germany) extraction followed by ethanol precipitation. The spectrophotometric absorbance of RNA samples at 230, 260 and 280 nm and ratios of D260: D280 and D260:D230 were measured spectrophotometrically (NanoDrop 2000; Thermo Scientific), to determine the purity and concentration of total RNA. A quantity of 1 lg of purified RNA was used for first-strand cDNA synthesis using 'Superscript III Reverse Transcriptase' and random hexamers in a final volume of 20 lL according to manufacturer's instruction (Invitrogen Life Technologies). Real-time quantification of gene expression was performed using a SYBR Green qPCR assay (Applied Biosystems, Foster City, CA, USA) or TaqMan 5'FAM-and 3'TAMRA-labelled fluorescent probes (Eurofins MWG, Ebersberg, Germany). PCR was performed using an 'ABI 7500' realtime PCR system and software (Applied Biosystems, RRID: SCR_014596) with standard cycling conditions: 40 cycles of 10 s at 95°C, 60 s at 60°C. Specificity of the PCR product was confirmed by examination of the dissociation reaction plot and PCR product detection on 2% agarose gel. Primers were designed by using Primer Express software (Applied Biosystems, RRID: SCR_014326). The sequences of all PCR primers used are available on request. The samples were run in duplicates and relative gene expression was calculated using the 2 ÀDDCt method, in which Ct indicated the fractional cycle number at which the fluorescent signal reached detection threshold. The normalised DCt value of each sample was calculated using the expression of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) as an endogenous control gene. Fold change values were presented as average fold change = 2 (average DDCt) for genes in nimodipine or vehicle-treated mice relative to those in naive mice. The statistical significance of differences in gene expression between the groups was calculated using a two-tailed Student's t-test (p < 0.05).
Statistical analysis EAE data were analysed by non-parametric tests. Group comparisons were performed with Mann-Whitney U-test, the correlation coefficient (r 2 ) was calculated by Pearson's test. For other experiments, one-way ANOVA or Student's t-test was used, and data distribution was assumed to be normal. An outlier analysis was not performed. In all experiments, a p value < 0.05 was defined as a statistically significant. All statistical tests were performed with GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA, RRID:SCR_015807).
Results
Nimodipine reduces the severity of relapsing-remitting EAE in SJL/J mice We first analysed the preventive effect of nimodipine in EAE induced in SJL/J mice, leading to a relapse-remission course upon immunisation with PLP [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] (Fig. 1a) . Daily administration of nimodipine (10 mg/kg body weight; i.p. according to Singh et al. 2016) did not affect the onset and severity of the first acute phase of EAE (first 20 days) and second relapse. However, nimodipine treatment resulted in a milder disease course thereafter. We observed a significant decrease in the mean of cumulative clinical scores in the nimodipine group during the remission phase (28-43 days p.i.; 13.0 AE 0.9 vs. 16.7 AE 0.5; p < 0.05) and decreased paralysis scores for the rest of the experiment (46-54 days p.i.; 16.9 AE 0.7 vs. 22.6 AE 0.9; p < 0.001) as compared to the vehicle group (Fig. 1a) .
Analysis of immune response in nimodipine-treated EAE
We analysed whether treatment with nimodipine had an impact on the autoimmune response in EAE mice. Splenocytes that were isolated from animals shown in Fig. 1(a) at 54 days p.i. and restimulated with the encephalitogenic PLP peptide for 72 h showed a similar proliferative response between the groups (Fig. 1b) . Flow cytometry analysis of lymphocyte subsets did not reveal significant ex vivo changes in proportion of CD4 + , CD8 + , CD19
+ cells (Fig. 1c) . Similarly, we did not observe nimodipine effects in such preventively treated C57BL/6 mice regarding lymphocyte subset distribution, proliferation and T-cell activation markers CD25, CD44, CD69 and ICAM1 upon specific ) and unspecific (anti-CD3) TCR stimulation ( Figure S1 ). Thus, the beneficial effect of nimodipine in amelioration of EAE could not be directly linked to an altered immune response.
Nimodipine leads to histopathological amelioration in SJL/J EAE Next, we examined the effect of nimodipine on CNS damage. Histopathological analysis revealed reduced demyelination and axonal loss (assessed by immunohistochemistry for MBP and neurofilament-M immunoreactivity, respectively) in lesioned areas of cerebellum and spinal cord of nimodipine-treated mice (representative images and quantification in Fig. 2a and b) . The extent of axonal damage showed a significant positive correlation with the clinical score (Fig. 2c) .
Intervention with nimodipine ameliorates severity of preestablished SJL/J and C57BL/6 EAE Next, we analysed whether intervention with nimodipine might protect mice with pre-established, ongoing EAE from irreversible damage and disability (i.e. 'therapeutic' treatment paradigm). Moreover, given the heterogeneity of disease models, we were interested in examining our findings in independent EAE models with regard to background strain and autoimmune target. To this aim, SJL/J mice were immunised with PLP 139-155 peptide and, upon reaching the clinical score 2.5-3 (12 days post-immunisation), were randomly distributed in two groups (vehicle n = 9 and nimodipine n = 9). Nimodipine treatment ameliorated the disease severity in acute phase (16-23 days p.i.; p < 0.001) and during relapse (27-36 days p.i.; p < 0.001) (Fig. 3a) , thus corroborating the results of Fig. 1(a) in a clinically more relevant setting.
In order to validate these findings in the SJL/J strain, we immunised C57BL/6 mice with MOG 35-55 peptide leading to a more chronic disease course (vehicle n = 5, nimodipine n = 8). A third, non-EAE group was sham-immunised with CFA lacking peptide and treated with vehicle as a reference control for biochemical analyses (n = 5 mice). Nimodipine treatment starting from day 10 (clinical score 3) ameliorated disease severity (13-26 days p.i.; p < 0.001). The vehicle group showed a non-remitting chronic phase which is typical for MOG-EAE in C57BL/6 mice, whereas the nimodipine group exhibited a remission starting shortly after administration (Fig. 3b) .
Myelin preservation in therapeutically treated C57BL/6 mice To assess, whether the beneficial effect of nimodipine is associated with prevention of myelin loss, we analysed the myelin content from the spinal cord of C57BL/6 EAE mice. As shown in Fig. 4(a) , protein analysis by western blotting for MBP showed a preservation of this essential myelin component in nimodipine-treated mice (19 and 26 kDa MBP isoforms). Optical density analysis revealed a significant difference of the MBP amount between vehicle and nimodipine groups (Fig. 4b) . Next, we confirmed this result by histological examination of spinal cord sections stained with Luxol fast blue for myelin. In white matter areas of nimodipine-treated mice, we observed a significantly increased in myelin content as compared to vehicle group ( Fig. 4c and d) .
Histopathological neuroprotection in therapeutically treated C57BL/6 mice To elucidate the effect of nimodipine on neurons, we analysed two commonly used hallmark proteins of axonal damage in MS, neurofilament H (NF-H) and post-synaptic protein PSD95. Nimodipine exhibited a neuroprotective effect by conserving the amount of NF-H and PSD95 ( Fig. 5a and b) . In line with this, evaluating the accumulation of amyloid precursor protein ovoids, as a marker of axonal injury, showed significantly less neuronal damage in nimodipine-treated mice ( Fig. 6a and b) .
Tissue inflammation in nimodipine-treated EAE mice Next, we aimed to assess the effect of nimodipine on the inflammatory response in the CNS. Immunostaining of spinal cord sections for microglia/macrophage marker Iba1 revealed diminished numbers of Iba1-positive cells in the nimodipine group as compared to vehicle (Fig. 7a  and b ). This effect appeared to be specific to white matter lesions, no changes in the Iba1-signal have been observed in cortical areas not directly affected by visible inflammation ( Fig. 7a and b) . To further examine potential effects of nimodipine on microglia, we examined the expression of inflammatory molecules secreted by microglia (TNFa, CCL5/RANTES, CCL11/eotaxin) and playing the key role in the pathogenesis of the disease. Using qPCR analysis, we did not observe significant changes in the expression profile of these molecules between vehicle and nimodipine-treated animals (Fig. 7c) . In line with this, histological examinations of MHC class I and iNOS, markers of activated microglia/macrophages, showed similar patterns of distribution around the perivascular infiltrations and comparable immunoreactivity ( Fig. 7d and e). 
Discussion
Here, we provide evidence for the primary neuroprotective effect of nimodipine in EAE, a common animal model for MS, with marked suppression of axonal injury and myelin loss. Our experimental approach confirms and extends previous work on the effects of the Ca 2+ channel blockers bepridil and nitrendipine in EAE (Brand-Schieber and Werner 2004) . Moreover, our data suggest that even longterm therapeutic administration of nimodipine at the dosage used in the present study has no obvious effect on the peripheral T-cell-mediated immune response, pointing to a primary CNS specific mode of action.
In the last two decades, increasing evidence of axon degeneration in MS lesions as well as normal-appearing white matter (Ferguson 1997; Trapp et al. 1998) , occurring at the very early stages of the disease (Filippi 2003) , shifted attention to neuroprotection as an important therapeutic goal (Franklin et al. 2012) . Regarding molecular targets at the axonal and neuronal level, increased intracellular Ca 2+ levels were suggested to contribute to neurodegeneration by activating detrimental proteolytic pathways such as calpainmediated protein cleavage (Stys and Jiang 2002; Bechtold et al. 2006) . The relevance of this cascade for disease progression was demonstrated in MS and EAE (Shields et al. 1999) . Upon inflammation, the activation of calpain subsequently leads to disruption of cytoskeleton homeostasis (involving the degradation of a broad spectrum of cytoskeleton proteins: neurofilaments, spectrin, tubulin, actin) and evokes myelinolysis (Banik et al. 1985) (particularly related to degradation of MBP and myelin-associated glycoprotein MAG (Shields et al. 1999) . In line, targeting calpain inhibition in EAE reduces CNS demyelination, axonal and neuronal damage and improves clinical signs of EAE (Guyton et al. 2009; Trager et al. 2014; Smith et al. 2016) . While the downstream events of Ca 2+ homeostasis disturbance was intensively studied in the context of numerous acute and chronic neurodegenerative conditions, the control of Ca 2+ influx remains elusive and is likely mediated by various mechanisms (Mattson 2007; Bezprozvanny 2009; Sargoy et al. 2014) .
Modulation of specific ion channels involved in Ca 2+ homeostasis represents a promising strategy because of the high diversity among different ion channel protein families and cell-type specificity (Ehling et al. 2011) . In MS, demyelinated and remyelinating axons, which express Na + channels and the Na + /Ca 2+ exchanger at high levels in both EAE (Craner et al. 2004a) and MS (Craner et al. 2004b) , are considered to be at increased risk of injury (Smith 2006) . Consistent with these findings, Na + blockers were shown to protect white matter axons in in vitro models of anoxic injury (Stys et al. 1992 ) and in EAE (Lo et al. 2002 (Lo et al. , 2003 . However, sodium blockers could not be translated successfully into the clinical setting so far (Kapoor et al. 2010) .
We hypothesised that nimodipine, a specific L-type Ca 2+ (Cav1.2) channel blocker, may be a promising neuroprotective compound since it has a favourable clinical safety profile, can be administered orally, crosses the blood brain Vehicle (n = 9) Nimodipine 10 mg/kg (n = 9) (a) (b) Figure 3 Intervention with nimodipine treatment in pre-established SJL/J and C57BL/6 experimental autoimmune encephalomyelitis (EAE) ('therapeutic treatment'). EAE was induced in female SJL/J mice by active immunisation with PLP 139-151 emulsified in Complete Freund's Adjuvant (CFA) (a) or female C56BL/6 mice with MOG 35-55 (b), followed by pertussis toxin injections. (a) At day 12, p.i. SJL/J mice with a score of 2.5-3 were equally randomised in two groups (vehicle n = 9 animals, white circles; nimodipine n = 9 animals, blue circles).
(b) Non-EAE sham-immunised C56BL/6 controls (n = 5 animals, black circles) were immunised with CFA lacking MOG-peptide, also followed by pertussis toxin injections. At day 10 p.i., EAE-immunised C56BL/6 mice animals with a score of 3 were randomised in two groups (vehicle n = 5 animals, white circles; nimodipine n = 8 animals, blue circles). Treatments were performed by daily i.p. injections beginning from day 12 (a) or day 10 (b). Data represent mean clinical scores in vehicle and nimodipine EAE animals. p value of cumulative clinical scores between the two groups in the indicated time period highlighted in grey (MannWhitney U-test).
barrier and easily reaches the CNS and CSF because of its lipophilic nature. In our study, we demonstrate that nimodipine improves clinical outcome in both relapsing-remitting murine SJL/J EAE and chronic C57BL/6 EAE. In both models, we observed a preservation of neuronal and myelin structures and did not observe differences in the peripheral Tcell-related immune response, which led us to hypothesise that blockade of L-type Ca 2+ channels may have a direct CNS-specific effect.
VGCCs are ion channels with permeability to Ca 2+ ; they are usually closed at resting potential and slowly open at depolarised cell potentials, increasing Ca 2+ influx and inducing long-lasting currents (Zuccotti et al. 2011) . In the brain tissue, L-type VGCCs have been shown to be associated with ryanodine receptors (intracellular Ca 2+ release channels) on endoplasmic reticulum and elicit Ca 2+ concentration in response to depolarisation (Ouardouz et al. 2003) . Originally, the importance of VGCC blockade for neuroprotective effect was underlined by the observation that the damage prevention is not achieved by exclusive blocking of the Na + /Ca 2+ exchange in a spinal cord ischaemia model (Stys et al. 1990) that VGCCs may represent an important route of Ca 2+ overload (Imaizumi et al. 1999) . Furthermore, in several animal models of neurotoxicity protective effects of nimodipine have been established and linked to its ability of inhibiting Ca 2+ influx and suppression of calpain activity. Thus, amelioration of motor deficits in rats evoked by administration of dichlorvos correlated with inhibition of intrasynaptosomal Ca 2+ accumulation and subsequent inhibition of calpain activity (Choudhary and Gill 2001) . Nimodipine suppresses calpain activity in hen brains in the model of organophosphorus-induced delayed neuropathy and ameliorates spinal cord lesions and clinical signs (Emerick et al. 2012) . Inhibitory effects of nimodipine on Ca 2+ sensitive phosphatase calcineurin have been demonstrated in hippocampal (Norris et al. 2002) and cortical neurons (Xiang et al. 2012) . Administration of nimodipine attenuated cytosolic calcineurin activity in the hippocampus of aged rats (Foster et al. 2001 ) and in the model of diffuse axonal injury in rats (Mu et al. 2015) .
Another intriguing aspect of VGCC modulation is the suppressive effect of VGCC on inhibition of microglia activation (Li et al. 2009; Tokuhara et al. 2010; Sanz et al. 2012) . Nimodipine inhibited microglia activation stimulated by amyloid beta (Sanz et al. 2012) and LPS (Li et al. 2009 ). It was proposed that suppression of microglia by nimodipine or genetic deletion of VGCC, and thus inhibiting the expression of proinflammatory cytokines, chemokines and production of reactive oxidative species, would have an indirect effect on protection of neurons (Li et al. 2009; Tokuhara et al. 2010) . In EAE, microglia have a major impact on disease initiation, immune cell infiltration and subsequent neuronal/ myelin damage, as shown by microglia depletion via genetic ablation (Heppner et al. 2005) , pharmacological inhibition (Ding et al. 2014) or microglia-specific modulation of NF-kB signalling pathway (Ellrichmann et al. 2012; Goldmann et al. 2013 ). While we did not detect overt changes in overall microglia distribution and microglia-related cytokine profile, we could show decreased numbers of Iba1-positive microglia/macrophages in the inflamed spinal cord tissue of nimodipine-treated animals. This effect could be secondary to a neuroprotective effect of nimodipine or directly mediated by nimodipine. During preparation of this manuscript, an article by Schampel et al. went to press investigating the effect of nimodipine on microglia in EAE (Schampel et al. 2017) . In this study, nimodipine affected the survival of microglia in vivo and in vitro leading to depletion of this population promoting neuronal and myelin integrity. The mechanism of nimodipine-induced microglia ablation is unknown and has been shown by Schampel et al. to be independent of VGCC. Importantly, however, in a quite sophisticated analysis Schampel et al. did not find T-cell function to be crucially involved in the phenotype of nimodipinetreated EAE, thus corroborating our data on the peripheral immune response. Thus, both studies suggest that nimodipine has a primary CNS-specific effect and may therefore represent a novel treatment paradigm considering that at present all available treatment options in MS target the peripheral immune system.
Conclusion
Our data suggest that nimodipine confers axonal and myelin protection in two common EAE paradigms without overt modulation of the primary immune response. Nimodipine may emerge as a novel neuroprotective approach and might show synergistic effects with currently used immunomodulatory substances approved for MS. Further studies aiming at clarifying the precise molecular pathways involved in neuroprotective effects of nimodipine are warranted.
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